Other Clinical Guidelines

The guidelines that ASH has developed can be found on the ASH Clinical Practice Guidelines page.

Requests for ASH Endorsement of External Guidelines

ASH does not formally endorse external guidelines or guidance documents but rather focuses on dissemination and implementation (D/I) strategies for external guidelines with the level of D/I effort aligned with the level of the guidelines’ quality and potential for impact on the field. ASH will review guidelines to determine whether the content is relevant to the practice of hematology and in line with the Institute of Medicine (IOM) standards. To submit a guideline for consideration of review, please download the checklist and send to [email protected].

ASH provides links to the following clinical guidelines as a service to our members.

2021

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
On January 6, 2021, the American Society of Hematology (ASH) affirmed these guidelines have value for hematologists. The guideline panel that developed them included one ASH representative, and the final guidelines were reviewed by the Guideline Oversight Subcommittee and Committee on Quality. ASH did not otherwise have input into the development of these guidelines.

Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia
On March 3, 2021, the American Society of Hematology (ASH) affirmed that these guidelines have value for hematologists. The guideline panel that developed them did not include an ASH representative, and the final guidelines were reviewed by the Guideline Oversight Subcommittee and Committee on Quality. ASH did not otherwise have input into the development of these guidelines.

2020

Laboratory Workup of Lymphoma in Adults: Guideline From the American Society for Clinical Pathology and the College of American Pathologists
On March, 20, 2020 the American Society of Hematology (ASH) affirmed that these guidelines have value for hematologists. The final guidelines were reviewed by the Guideline Oversight Subcommittee and the Committee on Quality. The guideline panel that developed them included three ASH representatives and the final guidelines were reviewed by the Guideline Oversight Subcommittee and Committee on Quality. ASH did not otherwise have input into the development of these guidelines.

The Society for Obstetric Anesthesia and Perinatology Interdisciplinary Consensus Statement on Neuraxial Procedures in Obstetric Patients With Thrombocytopenia
On October 9, 2020, the American Society of Hematology (ASH) affirmed that this consensus statement has value for hematologists. The consensus panel that developed the statement included three ASH representatives, and the final statement was reviewed by the Guideline Oversight Subcommittee and Committee on Quality. ASH did not otherwise have input into the development of this consensus statement.

Use of inferior vena cava (IVC) filters in the treatment of patients with thromboembolic disease
These guidelines were developed by the Society of Interventional Radiology (SIR) to provide evidence-based recommendations on the use of (IVC filters in the treatment of patients with or at substantial risk of venous thromboembolic disease. On June 19, 2020, the American Society of Hematology (ASH) affirmed that these guidelines have value for hematologists. The guideline panel that developed them included an ASH representative and the final guidelines were reviewed by the Guideline Oversight Subcommittee and Committee on Quality. ASH did not otherwise have input into the development of these guidelines. For more information on these guidelines, please visit here.

2019

Clinical Practice Guideline: Nosebleed (Epistaxis)
These guidelines were developed by the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) to identify opportunities for improvement in the management of nosebleed and to provide clear recommendations in clinical practice. On November 22, 2019, the American Society of Hematology (ASH) endorsed this guideline. The guideline panel that developed them included an ASH representative and the final guidelines were reviewed by the Guideline Oversight Subcommittee and Committee on Quality. ASH did not otherwise have input into the development of these guidelines. For more information on these guidelines, please visit here.

Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline
These guidelines were developed by International Collaboration for Transfusion Medicine Guidelines (ICTMG) to optimize red blood cell transfusions administered to patients with sickle cell disease (SCD) and β‐thalassemia. On July 19, 2019, the American Society of Hematology (ASH) affirmed that these guidelines have value for hematologists. The guideline panel that developed them included an ASH representative, and the final guidelines were reviewed by the Guideline Oversight Subcommittee and Committee on Quality. ASH did not otherwise have input into the development of these guidelines.

Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence‐based practice, an international approach
These guidelines were developed by International Collaboration for Transfusion Medicine Guidelines (ICTMG) to provide evidence‐based recommendations for the diagnosis and management of fetal and neonatal alloimmune thrombocytopenia, FNAIT. On July 19, 2019, the American Society of Hematology (ASH) affirmed that these guidelines have value for hematologists. The guideline panel that developed them included an ASH representative, and the final guidelines were reviewed by the Guideline Oversight Subcommittee and Committee on Quality. ASH did not otherwise have input into the development of these guidelines.

2018

Clinical Practice Guidelines for Quality Palliative Care, fourth edition
The guidelines were developed by the National Consensus Project for Quality Palliative Care, comprised of 16 national organizations with extensive expertise in palliative care and hospice. On August 31, 2018, the American Society of Hematology (ASH) affirmed that these guidelines have value for hematologists. ASH did not have input into the development of these guidelines, but the final guidelines were reviewed by the ASH Working Group on Palliative Care, Guideline Oversight Subcommittee, and Committee on Quality.

ASCO Guidelines on Managing Toxicities of Checkpoint Inhibitors
On June 8, 2018, the American Society of Hematology (ASH) affirmed that these guidelines have value for hematologists. The guideline panel that developed them included an ASH representative, and the final guidelines were reviewed by the ASH Task Force on Immunotherapies, Guideline Oversight Subcommittee, and Committee on Quality. ASH did not otherwise have input into the development of these guidelines.

Appropriate Use Criteria for Ventilation-Perfusion Imaging in Pulmonary Embolism
This appropriate use criteria was prepared by the Society of Nuclear Medicine and Molecular Imaging (SNMMI). On November 9, 2018, the American Society of Hematology (ASH) endorsed these appropriate use criteria. Based on this criteria, SNMMI developed the following valuable tool for physicians for determining the best diagnostic path for patients: SNMMI AUC Factsheet for Ventilation-Perfusion Imaging in Pulmonary Embolism.

2017

McMaster RARE‐Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome
On July 18, 2017, the American Society of Hematology (ASH) endorsed this guideline. This guideline for catastrophic antiphospholipid syndrome (CAPS), was prepared by the he McMaster RARE‐Bestpractices project group. The guideline panel included two ASH representatives.

2016

National Hemophilia Foundation-McMaster University Guideline on Care Models for Hemophilia Management
This guideline was endorsed by ASH on May 27, 2016, and published in Hemophilia on June 27, 2016.